In fact, in the hematopoietic cells of MDS patients, the reduced expression of SMAD7 was associated with an overactivation of SMAD2/3 signaling, even in the presence of low TGF-β concentrations. This evidence concerns the gene SMAD7 and myelodysplastic syndrome.